[Ip-health] Open letter supporting Italy's proposed resolution on Improving the transparency of markets for drugs, vaccines and other health-related technologies

Thiru Balasubramaniam thiru at keionline.org
Thu Mar 7 06:37:01 PST 2019


https://www.keionline.org/29902

Open letter supporting Italy’s’ proposed resolution on Improving the
transparency of markets for drugs, vaccines and other health-related
technologiesPosted on March 7, 2019 by StaffOn March 6, 2019, 83 civil
society organizations and 20 individuals asked delegates to the World
Health Assembly (WHA) to support a proposed resolution on “Improving the
transparency of markets for drugs, vaccines and other health-related
technologies.” A copy of the open letter is available below, and also as a
PDF file.

Open-Letter-WHA-Transparency-Resolution-6March2019
<https://www.keionline.org/wp-content/uploads/Open-Letter-WHA-Transparency-Resolution-6March2019.pdf>

For context, on February 1, 2019, the government of Italy submitted the
text of draft resolution to the WHO, with a cover letter noting the aim of
providing an “authoritative mandate to strengthen WHO’s technical work on
the transparency of the costs of research and development and the
transparency of prices” for discussion under agenda item 11.7 – Addressing
the global shortage of, and access to, medicines and vaccines, during the
72nd session of the World Health Assembly (WHA) in May 2019.

A PDF copy of the letter from Dr. Giulia Grillo, Italy’s Minister of
Health, and the draft resolution are attached here:

italy-letterWHO-DGTedros-resolution transparency
<https://www.keionline.org/wp-content/uploads/italy-letterWHO-DGTedros-resolution-transparency.pdf>

italy-draft-resolution-transparency-72WHA
<https://www.keionline.org/wp-content/uploads/italy-draft-resolution-transparency-72WHA-.pdf>

The Italian proposal follows a long line of recommendations for greater
transparency of the value chain for medical technologies, including the
many outlined here:

Background-Transparency-15Feb2019
<https://www.keionline.org/wp-content/uploads/Background-Transparency-15Feb2019.pdf>

The open letter follows:
------------------------------

March 6, 2019
Open letter to WHO member states

On 1 February 2019, Italy submitted a draft resolution on transparency to
the World Health Organization (WHO). This resolution is to be discussed in
May 2019, at the 72nd session of the World Health Assembly (WHA).

The title of the proposed resolution is “Improving the transparency of
markets for drugs, vaccines and other health-related technologies,” and it
sets out a number of measures designed to achieve this objective .

There are deplorable asymmetries of access to information about many
aspects of the innovation and supply chain for medicines, vaccines and
other health technologies. The lack of information creates confusion about
basic facts related to prices, research and development costs and other
aspects of the value chain for medicines, vaccines and health technologies.

The resolution would create a work program for the WHO and norms for
governments to cooperate in improving the transparency of various aspects
of these technologies.

This is a critical time for governments to consider reforms in pricing and
incentives for innovation for health technologies. The transparency
measures proposed in the resolution will ensure that consideration of such
reforms will be based upon the best possible evidence.

We urge your government to support the resolution.

*Organizations (in alphabetical order)*

   1. Access to Medicines Ireland (Ireland)
   2. Accion Internacional para la Salud – Perú
   3. Action against AIDS (Germany)
   4. ACTION Global Health Advocacy Partnership (Global)
   5. AIDES (France)
   6. AIDS and Rights Alliance for Southern Africa (ARASA)
   7. AIDS Healthcare Foundation (AHF) (US)
   8. Alliance for Reproductive Health Rights (ARHR) (Ghana)
   9. Associação Brasileira Interdisciplinar de AIDS (ABIA) (Brazil)
   10. Ben Newman Hope Care Foundation (Ghana)
   11. Botswana Network on Ethics, Law and HIV/AIDS (BONELA) (Botswana)
   12. BUKO Pharma-Kampagne (Germany)
   13. Cancer Alliance (South Africa)
   14. Center for Health, Human Rights and Development (CEHURD) (Kampala,
   Uganda)
   15. Centre for Community Studies, Action and Development (CENCOSAD)
   (Ghana)
   16. Chasing Zero (UK)
   17. Coalition Plus
   18. Commons Network (EU)
   19. Consumer Association the Quality of LIfe – EKPIZO (Greece)
   20. Drug for Neglected Diseases Initiative (DNDi)
   21. Empower India (India)
   22. European Alliance for Responsible R&D and Affordable Medicines
   23. European Public Health Alliance (EPHA)
   24. France Assos Santé (France)
   25. Global Health Advocates (France)
   26. Global Justice Now (UK)
   27. Groupe sida Genève – (Switzerland)
   28. Grupo de Trabalho sobre Propriedade Intelectual (GTPI) (Brazil)
   29. Health Action International (HAI)
   30. Health Gap
   31. Health Innovation in Practice (HIP)
   32. Heart to Heart Foundation (Thailand)
   33. Hepatitis Scotland (UK)
   34. IFARMA Foundation (Colombia)
   35. Interfaith Center for Corporate Responsibility (ICCR)(US)
   36. International Treatment Preparedness Coalition (ITPC)
   37. Just Treatment (UK)
   38. KEI Europe (Switzerland)
   39. Kenya Legal & Ethical Issues Network (KELIN) (Kenya)
   40. Kenyan Network of Cancer Organizations (KENCO) (Kenya)
   41. Knowledge Ecology International (KEI)
   42. Korean Pharmacists for Democratic Society (KPDS) (South Korea)
   43. Malawi Network of Religious Leaders Living with or Personally
   Affected by HIV and AIDS (MANERELA+) (Malawi)
   44. Médecins du Monde International
   45. Médecins Sans Frontières Access Campaign
   46. Misión Salud (Colombia)
   47. NCD Alliance East Africa (EANCDA)
   48. Non Communicable Disease Alliance of Kenya ( NCD-AK) (Kenya)
   49. Oxfam
   50. Pan African Positive Women’s Coalition-Zimbabwe
   51. Pan-African Treatment Access Movement (PATAM)
   52. People’s Health Institute (PHI) (South Korea)
   53. People’s Health Movement (PHM)
   54. PHM East Africa
   55. PHM Kenya
   56. Positive Malaysian Treatment Access & Advocacy Group (MTAAG+)
   (Malaysia)
   57. Prescrire (France)
   58. Public Citizen (US)
   59. Public Eye (Switzerland)
   60. Réseau Accès aux Médicaments Essentiels (RAME) (Burkina Faso)
   61. Salud por Derecho (Spain)
   62. Salud y Farmacos (USA)
   63. Save the Children
   64. SECTION27 (South Africa)
   65. Solthis (France)
   66. Southern African Programme on Access to Medicines and Diagnostics
   67. STOPAIDS (UK)
   68. T1International
   69. Tanzania Breast Cancer Foundation (Tanzania)
   70. Third World Network (TWN)
   71. Test Aankoop/Test Achats (Belgium)
   72. Trans Atlantic Consumer Dialogue (TACD)
   73. TranspariMED (UK)
   74. Treatment Action Group (TAG) (United States)
   75. Treatment Advocacy and Literacy Campaign (TALC) – Zambia
   76. Uganda NCD Alliance (Uganda)
   77. Union for Affordable Cancer Treatment (UACT)
   78. Universal Access to Health Care Campaign (UAHCC) (Ghana)
   79. Universities Allied for Essential Medicines (UAEM)
   80. Wemos (Netherlands)
   81. Women’s Coalition Against Cancer ( WOCACA) (Malawi)
   82. Yolse (Switzerland)
   83. Young Professionals Chronic Disease Network (YP-CDN)

*Individuals (in alphabetical order)*

   1. Aidan Hollis, Professor of Economics, University of Calgary.
   2. Amy Kapczynski, Professor of Law, Yale Law School, Faculty
   Co-Director of the Global Health Justice Partnership, and Faculty
   Co-Director of the Collaboration for Research Integrity and Transparency.
   3. Brook Baker, Professor of Law, Northeastern University, School of
   Law, Research Fellow, University of KwaZulu Natal in Durban, South Africa.
   4. Diane Singhroy, PhD, Research Associate, McGill University.
   5. Ellen ‘t Hoen, LLM, PhD. Director, Medicines Law & Policy.
   6. Fifa Rahman, Board Member Unitaid NGO Delegation and PhD Candidate
   (International Trade and Intellectual Property), University of Leeds.
   7. Gilberto de Lima Lopes Junior, MD, MBA, FAMS, Associate Professor of
   Clinical Medicine Medical Director for International Programs Associate
   Director for Global Oncology Co-Leader, Lung Cancer Site Disease Group
   Sylvester Comprehensive Cancer Center at the University of Miami and the
   Miller School of Medicine.
   8. Hani Serag, Egyptian Foundation for Health for All.
   9. Hannes Braberg, Staff Scientist at University of California, San
   Francisco.
   10. Jorge Bermudez, MD, DSc, Head of the Department of Medicines and
   Pharmaceutical Policies, National School of Public Health/ Oswaldo Cruz
   Foundation, Member of the UN Secretary-General High-Level Panel on Access
   to Medicines.
   11. Lawrence Gostin, University Professor, Georgetown University,
   Washington, DC.
   12. Leeza Osipenko, PhD. Senior Lecturer in Practice, LSE.
   13. Margo A. Bagley, Asa Griggs Candler Professor of Law, Emory
   University School of Law, Faculty Fellow, Emory Global Health Initiative
   (EGHI), Senior Fellow, Centre for International Governance Innovation
   (CIGI), Collaborator, Harvard University Global Access in Action (GAiA)
   Program.
   14. Mariana Mazzucato, Professor in the Economics of Innovation and
   Public Value, University College London; Founder and Director, the UCL
   Institute for Innovation and Public Purpose.
   15. Marie-Paule Kieny, PhD. Director of Research, Institut national de
   la santé et de la recherche médicale (INSERM), Chair, Drugs for Neglected
   Diseases Initiative Board of Directors, and Chair, Medicines Patent Pool
   Foundation Governance Board.
   16. Melissa Barber, PhD student, Harvard University.
   17. Ophira Ginsburg, Associate Professor, Department of Population
   Health, New York University School of Medicine.
   18. Ravi Ram, Director, RMH Systems, and Independent Health Systems
   Evaluator, Kenya.
   19. Suerie Moon, MPA, PhD. Director of Research at the Global Health
   Centre, Graduate Institute of International and Development Studies, Geneva
   and Adjunct Lecturer on Global Health at the Harvard T.H. Chan School of
   Public Health.
   20. William “Terry” W. Fisher III. WilmerHale Professor of Intellectual
   Property Law at Harvard Law School and Faculty Director of the Berkman
   Center for Internet and Society.




-- 
Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org


More information about the Ip-health mailing list